SV Angel is a San Francisco-based venture fund. Their experience spans helping companies like Airbnb, Coinbase, Databricks, DoorDash, Faire, Flexport, GitHub, Notion, Pinterest, Snap, Square, and Stripe Scale. Over the last 30 years of investing, their core values of trust, loyalty, and integrity along with a founder-first approach have driven our strategy. They are a service organization, investing in founders who share these values. They support entrepreneurs in building lasting companies by assisting at key inflection points and leveraging networks to help them propel their businesses forward.

SV Angel

Initialized Capital is an early-stage venture capital firm focused on the seed. Initialized has 6 investing partners and over $3.2B under management over five core funds since its founding in 2012. The firm's startups have created in aggregate over $200B in market value so far.

Initialized Capital

Formation 8 is a venture capital firm that provides financial and strategic capital to early growth smart enterprise and energy technology companies. They support entrepreneurs who seek to transform the most important global industries by solving hard problems with technology solutions. Partnership is in their DNA. Formation 8 value trusted relationships with entrepreneurs, investors, and strategic partners through their global network.  As a partner to young companies, Formation 8's goal is to create long-term, sustainable value through operational expertise and business development partnerships. Formation 8 leverage their deep and distributed networks to provide the market knowledge, deployment expertise, sales channels, and relationships needed to expand into and thrive in Asia. With local teams in Korea, China and Singapore, Formation 8 connect Silicon Valley start-ups to dynamic multinational corporations in these geographies.

Formation 8

AME Cloud Ventures focuses on seed to later stage companies building infrastructure and value chains around data. It specializes in technology-heavy companies gathering or creating unique data at every stage of the data stack — from infrastructure all the way to applications, mobile, and sensors.  It strives to find, fund, and support true entrepreneurs. The firm provides a unique and genuine set of resources to our founding teams, from strong operational and business experience to networks of amazing mentors and international partners, particularly in China. AME Cloud Ventures is the venture fund led by Jerry Yang, co-founder of Yahoo!

AME Cloud Ventures

Khosla Ventures invests in companies that are bold, early, and impactful. The firm was started in 2004 by Vinod Khosla, co-founder of Sun Microsystems, to provide venture assistance to entrepreneurs. Khosla Ventures invests in a range of areas including AI, climate, sustainability, enterprise, consumer, fintech, digital health, medtech and diagnostics, therapeutics, and frontier technology.

Khosla Ventures

#ANGELS is an investment collective. In addition to investing in phenomenal companies,  their mission is to get more women on the cap tables of successful startups. As investors, they back ambitious founders pursuing bold ideas. They collectively have a portfolio of 80+ companies across a wide range of industries.

#Angels

LeFrak is a preeminent, family-owned property company committed to community development and long-term ownership. Its investments are geographically diverse and span many business sectors. It has significant investments in securities, private businesses, and energy.

LeFrak

General Catalyst is a venture capital firm that provides early-stage and growth equity investments. The company provides ongoing momentum that accelerates ideas, careers, and companies toward standout success.

General Catalyst

Shasta Ventures invests in startups in sectors. Their program consists of a proven methodology and a set of comprehensive playbooks that dive deep into the obstacles and challenges of early-stage startups. There is no one-size-fits-all when it comes to early-stage, so this agile program allows founders to tap into the resources they need when they need them.

Shasta Ventures

Brainchild is a collective of engineers, operators, and designers that create products and services to solve some of the most significant problems facing consumers in healthcare, technology and consumer products. They consist of HERO, Onomie and The Arrivals.They also operate in both a technical and creative environment.  Brainchild also teams up with exceptional entrepreneurs to support their vision becoming a reality. To date, BCH has invested in 120 companies, 250 founders, with $4BB in follow-on capital, introductions, talent, growth, product, financing and strategy. Brainchild Holding’s seed investments include well-known companies such as Warby Parker, Oscar, sweetgreen, ClassPass, Tilt, Docker, Outdoor Voices, Gusto, Harry’s, Elysium, Seatgeek, and Smart Things; We also strategically support venture and later stage businesses.

Brainchild Holdings

Emerson Collective is an organization dedicated to removing barriers to opportunity so people can live to their full potential. Established and led by Laurene Powell Jobs, we center our work on education, immigration reform, the environment, and other social justice initiatives. We use a wide range of tools and strategies—partnering with entrepreneurs and experts, parents and policymakers, advocates and administrators—to develop and execute innovative solutions that will spur change and promote equality.

Emerson Collective

Caffeinated Capital is a technology venture capital firm that partners with founders at the inception stage and invest throughout the life of the company.

Caffeinated Capital

Jaws Ventures provides growth capital to companies with a focus on those operating in the consumer & technology sectors.

Jaws Ventures

8VC seeks to enable industry transformation. In a wave of creative destruction, they believe emerging platforms will replace the decades-old technology infrastructure behind many industries, promoting greater innovation and prosperity.

Founded in 2012, LionTree is an independent investment and merchant bank with deep roots in the media, technology, communications, consumer, and creative industries. LionTree's thematic focus and expertise provide a differentiated perspective to help their relationships unlock growth and transformation across key areas of the global digital economy.

LionTree

CRV has been an investor in technology companies for almost half a century. The firm has backed nearly 400 startups in its 47-year history, including foundational companies like Twitter, Zendesk, Amgen, Hubspot, Parametric Technologies, Yammer, EqualLogic, and Sonus Networks. Half of the companies CRV has backed have gone public or been acquired. The firm focuses on enterprise, consumer, and deep-insight bioengineering.

Pegasus Tech Ventures is a Silicon Valley-based venture capital firm working with emerging technology companies across the world, and specialize in helping entrepreneurs achieve global expansion into North America, Asia, and Europe. Our 100+ person team operates out of offices across 7 different countries and offers a wide range of domain expertise. Pegasus Tech Ventures currently has several multi-million dollar funds under management. We seek to work with world-class management and technical teams that are targeting disruptive opportunities in IT, Health IT, Artificial Intelligence, IoT, Robotics, Big Data, Virtual Reality, Augmented Reality, Quantum Computing, FinTech, and Next Generation Technologies.

Pegasus Tech Ventures

T. Rowe Price is an investment management firm dedicated to funding technology startups. The firm serves individuals, financial intermediaries, and institutions and offers a full range of investment strategies across a broad spectrum: debt, equities, and private equities.

T. Rowe Price

Viking Global Investors is an investment firm that uses fundamental analysis to select investments across industries and geographies. It is a global investment firm managing more than twenty billion in capital across long-short equity and long-only strategies. The firm was established in 1999 and is headquartered in Greenwich, Connecticut, with offices in New York City, Hong Kong, and London.

Viking Global Investors

Kindred Ventures is a seed-stage venture capital fund that supports startup companies. The company prefers to invest in the software, healthcare, telecommunications, retail, climate technology, and consumer industries. It is based in San Francisco, California, and was founded in 2014 by Steve Jang and Kanyi Maqubela.

Kindred Ventures

WR Hambrecht is a financial services firm that helps companies of all sizes access capital at the lowest cost in order to accelerate disruptive growth. Its philosophy is based on tenants such as identifying companies, helping them raise capital and go public, and delivering market pricing. The company has a wide range of products such as the OpenIPO Auction, the A+ IPO, the OpenBook Auction, and the OpenFollowOn Auction. Their clients are NETSUITE, Google, MORNINGSTAR, and XBiotech and it also offers initial public offering services to companies. WR Hambrecht is a U.S.-based company that was founded in 1998 by William and Robert Hambrecht.

WR Hambrecht

Color

Color is a complete platform for healthcare delivery from population genomics programs to high-throughput COVID-19 testing, Color provides the technology and infrastructure for large-scale health initiatives. Equitable, accessible healthcare programs. We bring together everything that’s required to run a large-scale healthcare program for your business, school, or state. Color’s products and services allow you to provide access to preventive healthcare programs whether your population is in one office or spread out across the country.

<div>Color Genomics is a precision genomics company that offers direct-to-consumer and B2B genetic testing services and provides insights into patient health risks in areas such as heart disease and cancer. The company&rsquo;s physician-ordered tests can be requested via its online platform, following which a sample collection kit is sent to the individual. Customers can choose between a hereditary cancer test that analyzes the sample for 30 genes associated with eight common hereditary cancers and the color extended test which identifies variants in 74 genes related to hereditary cancers, heart disease, and medication response. The color extended test kits are priced at USD 234. Individuals also have access to board-certified genetic counselors for a consultation through the platform.</div>

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

Color Health

**Color.com: Pioneering Digital Color Design**

<div>
 
 Color Genomics is a precision genomics company that offers direct-to-consumer and B2B genetic testing services and provides insights into patient health risks in areas such as heart disease and cancer. The company&rsquo;s physician-ordered tests can be requested via its online platform, following which a sample collection kit is sent to the individual. Customers can choose between a hereditary cancer test that analyzes the sample for 30 genes associated with eight common hereditary cancers and the color extended test which identifies variants in 74 genes related to hereditary cancers, heart disease, and medication response. The color extended test kits are priced at USD 234. Individuals also have access to board-certified genetic counselors for a consultation through the platform.
 
 
 The company collaborates directly with employers, unions, health systems, and governments to offer healthcare services related to preventive health and infectious disease management. By January 2021, its clients included Teamsters Union, the National Institutes of Health, Salesforce, the State of California, and United Airlines. In addition, the company offers Covid-19 testing, screening, and vaccine management services for large populations.
 
 
 Funding and financials
 
 
 The company raised USD 100 million in a Series E funding round in November 2021 led by Kindred Ventures, which valued the startup at USD 4.6 billion. The new funds were allocated toward expanding access to screening, diagnostics and treatments for individuals. The firm offerings will include vaccination and preventative health services for schools and employers, and it planned to offer infectious disease management programs in the future. The new funds came under a year since its Series D round (January 2021) which propelled it to unicorn status. 
 
 
 
</div>

<div>
 
 Praxis Precision Medicines is a clinical-stage biopharmaceutical company that develops precision medicine for central nervous system disorders based on neuronal imbalance caused by genetic mutations.
 
 
 The company has four clinical-stage product candidates in its pipeline for treating disorders such as depression, epilepsy, movement disorders, and pain syndromes. The company&rsquo;s drug candidates include 1) PRAX-944, which is an inhibitor for essential tremor disorder linked to Parkinson&rsquo;s disease and is set to begin Phase 3 in mid-2023, 2) PRAX-222 in Phase 2 of clinical trials targets the SCN2A gene most commonly associated with early-onset epilepsy, 3) PRAX-562 was designed to block persistent sodium for patients suffering from rare diseases such as headache disorders and severe seizures and completed Phase 1 of clinical trials, and 4) PRAX-628 in Phase 2 clinical trials for treating focal epilepsy that originates in one side or area of the brain and affects one side of the body. Additionally, the firm has six pre-clinical drug candidates.
 
 
 Funding and financials
 
 
 The company went public in October 2020, trading on the Nasdaq Global Select Market under the ticker symbol &ldquo;PRAX&rdquo;. 
 <a href="https://sp-edge.com/updates/19453">
 In June 2023 
 </a>
 , the company announced an underwritten public offering of its common shares and pre-funded warrants, to raise approximately USD 59.1 million. The capital raised was used to support the company&rsquo;s ongoing operations and strategic initiatives, furthering the development of its pipeline and potential future endeavors.
 
 
 For the year 
 <a href="https://sp-edge.com/updates/16211">
 2022
 </a>
 , net losses increased by 28% YoY to USD 214 million arising from a significant increase in R&amp;D expense (up by 29% YoY). For the six months ended June 2023, the company is yet to generate revenue from drugs, however received collaboration revenue of USD 1.5 million. Further, it reported a decline in net loss by 43.0% YoY to USD 34.3 million. Its cash and cash equivalent as of June 2023 was at USD 124.3 million, compared to USD 61.6 million in December 2022, which the company believes will be adequate to fund operations till Q1 2025. 
 
</div>

Praxis Precision Medicines

<div>
 
 Mirati Therapeutics is a commercial-stage biotechnology company developing oncology-targeted therapies to address KRAS mutations present in 25% of tumors, including lung, colorectal and pancreatic cancers. Mirati&rsquo;s lead product KRAZATI (adagrasib/ MRTX849) is an oral&nbsp; KRASG12C inhibitor approved in 2022 for certain non-small cell lung cancers.The company also has sitravatinib, a multi-kinase inhibitor, in Phase 3 trials for non-small cell lung cancer in combination with a Bristol-Myers Squibb checkpoint inhibitor.
 
 
 
 
 Additionally, Mirati is advancing multiple early-stage programs including KRAS G12D inhibitor MRTX1133 for pancreatic and colorectal cancers, which entered Phase 1 in 2023, as well as a synthetic lethal inhibitor MRTX1719. In December 2022, the company submitted an IND application for MRTX1133, a potent and selective KRAS G12D inhibitor, which was cleared by the FDA in January 2023. 
 
 
 Key partnerships and customers
 
 
 
 
 Mirati has multiple partnerships with leading biopharma companies to advance its pipeline, including discovery collaborations with Pfizer and clinical collaborations with Novartis, Boehringer Ingelheim, and 
 <a href="https://sp-edge.com/updates/14345">
 Incyte
 </a>
 . The company also has licensing agreements with BeiGene for sitravatinib and Zai Lab for MRTX849 in certain Asian markets.
 
 
 
 
 
 Funding and Financials
 
 
 
 
 The company went public in June 2013 to trade on Nasdaq under the ticker symbol &ldquo;MRTX&rdquo;. In August 2023, the company closed an 
 <a href="https://sp-edge.com/updates/20988">
 underwritten public offering
 </a>
 at USD 345 million. The new funds were used towards drug development and leadership expansion.&nbsp;
 
 
 
 
 <a href="https://sp-edge.com/updates/16725">
 For the year 2022 
 </a>
 , the firm's net losses increased to USD 740.9 million from USD 581.8 million. Net product revenue for the full year amounted to USD 0.7 million arising from the sale of KRAZATI, which received FDA approval for its commercial launch in December 2022. 
 
</div>

Mirati Therapeutics

<div>
 
 Tvardi Therapeutics is a clinical-stage biotechnology company developing precision medicine for different cancers, chronic inflammatory diseases, and fibrotic diseases. The company&rsquo;s pipeline focuses on the development of small-molecule inhibitors of STAT3, a regulatory protein that allows cancer cells to evade the immune system and survive.
 
 
 The company&rsquo;s orally administered monotherapy and lead product, TTI-101, is in Phase 1 clinical trials for patients with advanced solid tumors who have failed all other lines of therapy. Additionally, the drug is in preclinical trials for treating fibrosis and inflammation. The company is also developing TTI-102, a next-generation STAT3 inhibitor that is structurally similar but chemically different from TTI-101.&nbsp;
 
 
 Founded in 2017, the Texas-based company closed a Series B funding round in June 2021, which brought total funding to USD 81 million and the proceeds will be used to advance Tvardi&rsquo;s drug candidates through its clinical data readouts in mid-stage trials for cancer and fibrosis.
 
</div>

Tvardi Therapeutics

<div>
 
 Tango Therapeutics is a clinical-stage biotech company developing precision oncology therapies targeting synthetic lethality in cancer which leads to cell death. Its discovery platform identifies novel targets to develop drugs focused on: 1) countering tumor suppressor gene loss to help the immune system recognize and kill cancer cells, and 2) reversing cancer cell evasion of the immune system.
 
 
 
 
 Tango has five pipeline programs, including lead candidate TNG908, an inhibitor for multiple cancer indicators. The FDA approved TNG908's IND in January 2022 and granted it Orphan Drug Designation. TNG908 is in Phase I/II trials, with preliminary efficacy data expected in H1 2023. Tango also plans to file INDs for TNG260 (STK11 mutant cancers) and TNG348 (BRCA1/2-mutant cancers). In 
 <a href="https://www.globenewswire.com/news-release/2023/01/25/2595034/0/en/Tango-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-TNG462-Provides-Additional-Business-Updates.html">
 January 2023
 </a>
 , the FDA cleared the IND for TNG462, a next-gen PRMT5 inhibitor for cancers with MTAP deletion.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 
 Outside its pipeline, the company also entered into a collaborative partnership with big pharma Gilead Sciences Inc., in October 2018 which was later expanded for two years in August 2020 to identify new immune evasion targets.
 
 
 
 
 Funding and financials&nbsp;
 
 
 
 
 
 Tango went public in August 2021 via a SPAC deal, trading on Nasdaq under the ticker symbol &ldquo;TNGX&rdquo;, and the company received gross proceeds of USD 353 million. In August 2023, the company raised USD 80 million via a 
 <a href="https://sp-edge.com/updates/20955">
 private placement
 </a>
 , which was led by Nextech. The new funds were used toward expanding its TNG908 and TNG462 PRMT5 programs to various other indications.
 
 
 
 
 Tango has not yet generated any drug sales and does not expect to do so for several years. However, for the full-year the company reported collaboration revenue of USD 24.9 million (down 4.42% YoY) and a net loss of USD 108.2 million (up 85.9% YoY).
 
 
 
</div>

Tango Therapeutics

<div>
 
 IDEAYA Biosciences is a clinical-stage biotech developing precision cancer therapies based on synthetic lethality - when specific gene mutations pair to cause cell death. The company also studies combining synthetic lethality with immunotherapies and DNA damage to enhance treatment efficacy. While current drugs target limited mutations like BRCA1/2, IDEAYA aims to treat broader genetic subpopulations.&nbsp;
 
 
 
 
 Its pipeline includes synthetic lethality-driven precision medicines across four potential first-in-class clinical-stage product candidates. Of these, the company owns/controls commercial rights of the three most-advanced of these product candidates: darovasertib, IDE397, and IDE161. As of May 2024, the company was also advancing Werner Helicase program for which a development candidate has been selected in collaboration with GlaxoSmithKline, and, subject to investigational new drug-, or IND-, enabling studies, are targeting an IND in 2024. In addition. the company also works on multiple earlier-stage preclinical programs. 
 
 
 By targeting specific genetic drivers, IDEAYA advances precision oncology using synthetic lethality approaches. The company is focused on developing novel targeted therapies for patient populations with high unmet need and limited treatment options.&nbsp;&nbsp;
 
 
 In December 2023, IDEAYA Biosciences teamed up with Gilead Sciences to test the combination of IDE397 and Trodelvy in a Phase I clinical trial for MTAP-deletion bladder cancer.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 The company collaborates with pharmaceutical partners to advance its pipeline, including a strategic partnership with GSK in June 2020. The collaboration with GSK covers co-development and commercialization of two synthetic lethality programs. IDEAYA received USD 100 million upfront and USD 20 million in a direct private placement through the GSK deal. In June 2022, IDEAYA announced it would co-develop its Pol Theta candidate with GSK, with a Phase 1 trial starting in the first half of 2023.&nbsp;
 
 
 
 
 IDEAYA also holds an exclusive license from Novartis for LXS196 (IDE196), a PKC inhibitor for metastatic uveal melanoma. Additionally, the company is exploring IDE196 combinations with Pfizer and its potential in other rare skin diseases. In July 2022, IDEAYA signed an agreement with Amgen to evaluate IDE397 with Amgen's AMG 193 in solid tumors. Strategic pharma partnerships help advance and expand IDEAYA's pipeline of synthetic lethality precision oncology programs.
 
 
 
 
 Funding and financials
 
 
 
 
 
 The company was listed on the Nasdaq Global Select Market under the ticker symbol &ldquo;IDYA&rdquo; in May 2019, raising USD 50 million via an initial public offering. In September 2022, the company raised USD 92 million.&nbsp;
 
 
 
 
 For 2022, the company reported a net loss of USD 58.7 million (up 17.9% YoY) while collaboration revenue was USD 50.9 million (up 82.3% YoY). 
 
 
 On October 24, 2023, IDEAYA Biosciences priced an underwritten public offering of 5 million shares of common stock and pre-funded warrants to purchase 319,150 shares of common stock. The common stock offered was priced at USD 23.50 per share, while the exercise price of a pre-funded warrant was USD 0.0001. The offering was expected to bring in approximately USD 125 million in gross proceeds.
 
 
 
</div>

IDEAYA Biosciences

Companies providing genetic tests to identify individuals with high risk or at-risk of having hereditary disease, aid physicians with a diagnosis, and support clinical decision making.

Secure cloud-based platforms and data sharing networks that collect, index, store, and analyze large amounts of health data and patient population data sets from sources including genomic, clinical, wearables, imaging, and population data.

Biopharma and biotechnology companies that develop precision medicine drugs based on novel disease biomarkers present in multi-omic patient population data and genetic insights.

Companies that study intergenomic variations in genes associated with drug response and metabolism to match patients with the appropriate drug and dosage.

Companies that develop an in-vitro medical device or imaging tools and tests that identify genetic mutations for both diagnostic (nature of the disease) and prognostic (likely course of the disease) purposes, allowing providers to match a patient to a specific drug or therapy.

Software analytics platforms that integrate multiple omics datasets (genomics, transcriptomics, proteomics, and metabolomics) to gain insights and support target discovery, drug development, clinical trials, and diagnostics.

Some companies leverage AI/ML to develop tailored medication

Considers individual variability in genes, environment, and lifestyle for each person

Genomics is used across all the segments of precision medicine from diagnostic solutions to treatments

AI/ML analyzes genomic data to find drug targets, predict disease progression, and treatment response

New technologies are opening up mental health services to previously overbooked and underserved populations.

Color Health

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless